CellPrime
32 Results
Advanced Search
Showing
-
-
Press Release: Merck Introduces CellPrime%E2%84%A2 Recombinant Human Lysozyme for Increased Protein Recovery From E. coli Production Systems
Merck, today announced the launch of CellPrime%E2%84%A2 recombinant human lysozyme for increased recovery efficiencies in biopharmaceutical production. -
Non-animal Origin Supplements | Biopharmaceutical Manufacturing | Merck
Merck offers a variety of non-animal origin supplements, specifically formulated for cell culture applications. -
Press Release: Merck Announces Exclusive Supply and Marketing Agreement With Ventria Bioscience to Expand its CellPrime%E2%84%A2 Line of Non-animal Origin Products
Merck, today announced an exclusive collaboration with Ventria Bioscience through which Ventria will manufacture and supply a recombinant product that meets the requirements for use as a raw material in cGMP biopharmaceutical production. -
Cell Culture Ingredients and Supplements | Biopharmaceutical Manufacturing | Merck
Our portfolio of cell culture ingredients and supplements can help you stabilize your processes and obtain optimal yields with consistent results. -
Cleavage, Lysis and Purification after Harvest | Biopharmaceutical Manufacturing | Merck
Our products for the processing steps that follow cell harvest include Benzonase%C2%AE endonuclease for DNA removal and lysozomes for cell lysis. -
Press Release: Merck Announces Exclusive Agreement with Julphar Diabetes to Offer Non-animal Origin, Recombinant Human Insulin as Cell Culture Media Supplement
Merck, today announced an exclusive agreement to sell recombinant human insulin manufactured by the United Arab Emirates-based pharmaceutical production company Julphar Diabetes. -
Viral Safety Assurance | Prevent | Merck
Cell lines used for the production of biotherapeutics need to be extensively characterized before use to determine the levels of endogenous retrovirus-like particles, and whether unexpected adventitious virus is present in the source cells.